Astellas Sees Clouds Over Prograf, Irribow; Launches Vesicare In Asia To Drive Growth

Facing U.S. market expansion for generic Prograf (tacrolimus), a 14-year running blockbuster immunosuppressant, Japan's second-largest drug maker Astellas hopes to cultivate its next blockbuster from mirabegron, and ride the strong performance of Vesicare (solifenacin) to drive global growth by launching the drug in emerging Asian markets such as Singapore and China